The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled Acromegaly:
The 11th Acromegaly Consensus Conference in April 2024 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management
Kulesha also clarified that, in addition to oncology drugs, the procurement of medicines acromegaly, pulmonary hypertension, and
Octreotide is a medication used in the management and treatment of acromegaly and thyrotrophinomas. It is in the somatostatin analog class of drugs. This activity describes the indications, action, and contraindications for octreotide as a valuable agent in the management of acromegaly and thyrotrophinomas, as well as carcinoid syndrome. This activity also highlights the mechanism of action
U.S. Acromegaly Drugs Market Segmentation, By Disease Type, (Pseudo acromegaly, Ectopic Acromegaly), Drug Class, (Somatostatin Analogues, Growth Hormone
Achilles Tendonitis Acoustic Neuroma Acromegaly Acute Gabapentin Considerations and Patient Teaching [Drug Guide] General
Diabetes Drugs Glucocorticoids Obesity Drugs Thyroid Drugs Hypothalamic / Pituitary Drugs. Updated: Dec 8 2024. Pituitary Adenoma / Acromegaly.
GlobalData tracks 17 drugs in development for Acromegaly by 16 companies/universities/institutes. The top development phase for Acromegaly
In the US, Signifor LAR has orphan drug designation for acromegaly. Potential drug interactions with Signifor LAR may include drugs to
Comments